{
  "pmcid": "5079604",
  "config": {
    "model": "gemini",
    "strategy": "zero-shot"
  },
  "usage": {
    "input": 5735,
    "output": 1838
  },
  "raw_text": "Based on the provided article, here are the extracted arm-level statistics for the specified ICO triplets.\n\n**Extraction Logic:**\n\n*   **ICO 1 (Disposition index):** The article reports that DI was significantly higher in the remission group (Figure 2A), but does not provide explicit numerical values (mean/SD) in the text or tables. The values are only presented in a bar chart. -> **Nulls**.\n*   **ICO 2 (AUCi):** Similarly, incremental AUCi is plotted in Figure 2B and reported as significantly different, but no specific mean/SD values are textually reported. -> **Nulls**.\n*   **ICO 3 (Relapse-free survival, Met vs Sita, Continuous):** The text states there was \"no difference in hyperglycemia relapse-free survival between metformin and sitagliptin (P = 0.75)\". No mean survival times are reported separately for these two arms. -> **Nulls**.\n*   **ICO 4 (Cox proportional hazards, Met vs Sita, Continuous):** The text reports Hazard Ratios (0.28 and 0.31 vs placebo), but the requested schema (Mean/SD) cannot accommodate Hazard Ratios. -> **Nulls**.\n*   **ICO 5 (Restricted mean time, Combined vs Placebo, Continuous):** The text explicitly states: \"The restricted mean time to hyperglycemia relapse in the combined metformin and sitagliptin groups was significantly higher than placebo (480 vs. 305 days, P = 0.004).\"\n    *   Intervention (Combined Met+Sita): Mean = 480. Group Size = 17+16 = 33 (Analysis was ITT).\n    *   Comparator (Placebo): Mean = 305. Group Size = 15.\n    *   SDs are not reported.\n*   **ICO 6 (Hyperglycemia relapse-free survival, Combined vs Placebo, Continuous):** While related to ICO 5, no other continuous statistic (like mean survival) distinct from the restricted mean time is reported for this specific label. -> **Nulls**.\n*   **ICO 7 (2-year failure rate, Binary):** The text reports failure rates as percentages (\"77% vs 44%...\"). It does not provide the specific numerator (events) and denominator (N at risk) for the 2-year timepoint specifically (censoring applies). The raw counts correspond to the end of study. -> **Nulls**.\n*   **ICO 8 (Probability of relapse, Binary):** The text reports the number of subjects experiencing relapse: \"metformin [n = 5], sitagliptin [n = 4]) compared with placebo (n = 11)\".\n    *   Intervention (Combined Met+Sita): Events = 5 + 4 = 9. Group Size = 33.\n    *   Comparator (Placebo): Events = 11. Group Size = 15.\n\n```json\n{\n  \"extractions\": [\n    {\n      \"outcome\": \"Disposition index (DI)\",\n      \"intervention\": \"subjects who remained in remission\",\n      \"comparator\": \"patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": null,\n      \"comparator_events\": null,\n      \"comparator_group_size\": null,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"incremental area under the curve for insulin (AUCi)\",\n      \"intervention\": \"subjects who remained in remission\",\n      \"comparator\": \"patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": null,\n      \"comparator_events\": null,\n      \"comparator_group_size\": null,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"hyperglycemia relapse-free survival\",\n      \"intervention\": \"metformin 1,000 mg daily\",\n      \"comparator\": \"sitagliptin 100 mg daily\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": null,\n      \"comparator_events\": null,\n      \"comparator_group_size\": null,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"Cox proportional hazards of failure-free survival\",\n      \"intervention\": \"metformin 1,000 mg daily\",\n      \"comparator\": \"sitagliptin 100 mg daily\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": null,\n      \"comparator_events\": null,\n      \"comparator_group_size\": null,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"The restricted mean time to hyperglycemia relapse\",\n      \"intervention\": \"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\n      \"comparator\": \"placebo\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": 33,\n      \"comparator_events\": null,\n      \"comparator_group_size\": 15,\n      \"intervention_mean\": 480.0,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": 305.0,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"Hyperglycemia relapse-free survival\",\n      \"intervention\": \"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\n      \"comparator\": \"placebo\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": null,\n      \"comparator_events\": null,\n      \"comparator_group_size\": null,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"The 2-year failure rate\",\n      \"intervention\": \"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\n      \"comparator\": \"placebo\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": null,\n      \"comparator_events\": null,\n      \"comparator_group_size\": null,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"The probability of relapse\",\n      \"intervention\": \"metformin 1,000 mg daily, sitagliptin 100 mg daily\",\n      \"comparator\": \"placebo\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 9,\n      \"intervention_group_size\": 33,\n      \"comparator_events\": 11,\n      \"comparator_group_size\": 15,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    }\n  ]\n}\n```",
  "extraction": [
    {
      "outcome": "Disposition index (DI)",
      "intervention": "subjects who remained in remission",
      "comparator": "patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "incremental area under the curve for insulin (AUCi)",
      "intervention": "subjects who remained in remission",
      "comparator": "patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si)",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "hyperglycemia relapse-free survival",
      "intervention": "metformin 1,000 mg daily",
      "comparator": "sitagliptin 100 mg daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "Cox proportional hazards of failure-free survival",
      "intervention": "metformin 1,000 mg daily",
      "comparator": "sitagliptin 100 mg daily",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "The restricted mean time to hyperglycemia relapse",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 33,
      "comparator_events": null,
      "comparator_group_size": 15,
      "intervention_mean": 480.0,
      "intervention_standard_deviation": null,
      "comparator_mean": 305.0,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "Hyperglycemia relapse-free survival",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "The 2-year failure rate",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "binary",
      "intervention_events": null,
      "intervention_group_size": null,
      "comparator_events": null,
      "comparator_group_size": null,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    },
    {
      "outcome": "The probability of relapse",
      "intervention": "metformin 1,000 mg daily, sitagliptin 100 mg daily",
      "comparator": "placebo",
      "outcome_type": "binary",
      "intervention_events": 9,
      "intervention_group_size": 33,
      "comparator_events": 11,
      "comparator_group_size": 15,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5079604"
    }
  ]
}